Heart Disease Trial, Recruiting NCT07268859 Sponsor: Acibadem University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT07268859
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years old
  • People without severe hearing or vision problems
  • People who can speak and understand Turkish
  • People who are easy to communicate with
  • People experiencing acute coronary syndrome (a serious heart condition) for the first time
  • People who have decided to begin treatment with a medication called ticagrelor
  • People who are able to follow and adapt to their treatment plan
  • People who have chosen to volunteer to take part in the research

Who may not be able to join:

  • People who have any condition that makes communication difficult — whether cognitive, emotional, or verbal
  • People with obstructive sleep abnormalities (confirm with trial site)
  • People with a disease that affects breathing or lung function, such as stage IV cancer, asthma, COVID-19, lung cancer, fluid on the lungs, chronic obstructive pulmonary disease (COPD), high blood pressure in the lungs, pulmonary embolism, pneumonia, or bronchitis
  • People with metabolic abnormalities (problems with the body's chemical processes — confirm with trial site)
  • People who needed a breathing tube inserted after a procedure
  • People who have previously been treated with ticagrelor
  • People who have a blood oxygen level below 95%
  • People who have experienced a cardiac arrest
  • People who would not be able to meet the requirements of the study
  • People with life-threatening conditions
  • People who choose not to volunteer to participate
  • People who decide to leave the study after it has begun

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +905556177281

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Acibadem University
Registry
ClinicalTrials.gov
Start date
15 March 2025
Est. completion
10 January 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Incidence of ticagrelor-associated dyspnea

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov